$INO

Pomerantz LLP files class action against Inovio Pharmaceuticals for securities fraud over false FDA claims; stock fell 24.45% in December 2025.

Law offices announce securities fraud class actions against $PSFE, $INO, and $KD with lead plaintiff deadlines April 7-13, 2026.

Class action lawsuit filed against Inovio Pharmaceuticals for allegedly making false statements about manufacturing deficiencies and overstating regulatory prospects, triggering 24.45% stock decline.

Atara Biotherapeutics faces securities fraud class action for allegedly misrepresenting manufacturing capabilities and overstating regulatory prospects for tabelecleucel between May 2024 and January 2026.

Rosen Law Firm alerts $QURE investors with losses exceeding $100K to meet April 13 deadline in securities class action over alleged FDA approval status misrepresentation.

Rosen Law Firm urges Inovio investors with $100K+ losses to file by April 7 deadline in securities class action alleging false manufacturing and regulatory statements.

$INO faces securities fraud lawsuit alleging false statements about INO-3107 regulatory timeline and CELLECTRA device manufacturing. Stock fell 24.45% in December 2025 after FDA rejected accelerated review.

Inovio shareholders with $100K+ losses must meet April 7 deadline to join securities lawsuit alleging false statements about CELLECTRA device and INO-3107 FDA timeline.

Rosen Law Firm files securities class action against Trip.com Group ($TCOM), alleging false statements on business operations and regulatory risks. Investors urged to secure counsel before deadlines.

Rosen Law Firm is recruiting investors in $KD, Alight, and Inovio for securities class actions alleging false statements and inadequate disclosure.

Rosen Law Firm urges Inovio Pharmaceuticals investors with losses exceeding $100K to file claims before April 7, 2026 deadline in ongoing securities class action lawsuit.

Class action filed against $INO alleging executives made false statements about CELLECTRA device manufacturing and INO-3107 regulatory timeline between October 2023 and December 2025.

Rosen Law Firm alerts $INO investors of April 7, 2026 deadline to join class action over alleged false statements regarding manufacturing and regulatory prospects.

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

Law firm Levi & Korsinsky files class action against Inovio Pharmaceuticals for allegedly false statements regarding device manufacturing and FDA pathways from October 2023 to December 2025.

Rosen Law Firm seeks lead plaintiffs in securities class action against Inovio Pharmaceuticals for alleged misstatements on device defects, regulatory prospects, and product timelines. Lead plaintiff deadline: April 7, 2026.

Class action lawsuit filed against Inovio Pharmaceuticals ($INO) for allegedly making false statements about INO-3107 treatment and manufacturing capabilities, causing significant stock declines.

Inovio Pharmaceuticals faces a securities class action over allegedly false statements regarding manufacturing capabilities and regulatory prospects for INO-3107, following FDA's December 29 accelerated approval rejection.

Pomerantz Law Firm filed class action lawsuit against Richtech Robotics over alleged Microsoft partnership misrepresentation, citing 20.87% stock decline. Investors have until April 3, 2026, to join.

Pomerantz Law Firm files class action against $INO for alleged securities fraud involving false manufacturing capability and FDA approval claims for INO-3107.